1. Home
  2. IPHA vs EVC Comparison

IPHA vs EVC Comparison

Compare IPHA & EVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IPHA
    SELLHOLDBUYas of 3 days ago
  • EVC
    SELLHOLDBUYas of 3 days ago
  • Stock Information
  • Founded
  • IPHA 1999
  • EVC 1996
  • Country
  • IPHA France
  • EVC United States
  • Employees
  • IPHA N/A
  • EVC N/A
  • Industry
  • IPHA Biotechnology: Pharmaceutical Preparations
  • EVC Broadcasting
  • Sector
  • IPHA Health Care
  • EVC Industrials
  • Exchange
  • IPHA Nasdaq
  • EVC Nasdaq
  • Market Cap
  • IPHA 148.3M
  • EVC 229.5M
  • IPO Year
  • IPHA 2019
  • EVC 2000
  • Fundamental
  • Price
  • IPHA $1.69
  • EVC $2.36
  • Analyst Decision
  • IPHA Strong Buy
  • EVC Hold
  • Analyst Count
  • IPHA 1
  • EVC 1
  • Target Price
  • IPHA $11.50
  • EVC $1.75
  • AVG Volume (30 Days)
  • IPHA 49.9K
  • EVC 512.7K
  • Earning Date
  • IPHA 09-12-2024
  • EVC 03-04-2025
  • Dividend Yield
  • IPHA N/A
  • EVC 8.47%
  • EPS Growth
  • IPHA N/A
  • EVC N/A
  • EPS
  • IPHA N/A
  • EVC N/A
  • Revenue
  • IPHA $36,202,722.00
  • EVC $1,146,066,000.00
  • Revenue This Year
  • IPHA N/A
  • EVC N/A
  • Revenue Next Year
  • IPHA $101.65
  • EVC N/A
  • P/E Ratio
  • IPHA N/A
  • EVC N/A
  • Revenue Growth
  • IPHA N/A
  • EVC 122.49
  • 52 Week Low
  • IPHA $1.29
  • EVC $1.33
  • 52 Week High
  • IPHA $3.51
  • EVC $4.41
  • Technical
  • Relative Strength Index (RSI)
  • IPHA 42.95
  • EVC 48.24
  • Support Level
  • IPHA $1.60
  • EVC $2.28
  • Resistance Level
  • IPHA $1.87
  • EVC $2.70
  • Average True Range (ATR)
  • IPHA 0.13
  • EVC 0.16
  • MACD
  • IPHA -0.04
  • EVC -0.01
  • Stochastic Oscillator
  • IPHA 16.67
  • EVC 30.61

Stock Price Comparison Chart: IPHA vs EVC

IPHA
EVC
AprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025012345678910IPHA VS EVC

About IPHA Innate Pharma S.A. ADS

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.

About EVC Entravision Communications Corporation

Entravision Communications Corp is a global advertising solutions, media, and technology company. Its operations encompass integrated marketing and media solutions, comprised of television, radio, and digital properties and data analytics services. The company operates in television broadcasting, audio broadcasting, and digital media segments. The Company's digital segment, whose operations are located in Europe, Latin America, Asia, the United States, and Africa. The Company's television and audio operations reach and engage U.S. Hispanics in the United States.

Share on Social Networks:

0

By browsing this website, you accept our Privacy Policy & Terms of Use